Bellicum Pharmaceuticals (NASDAQ: BLCM)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-03 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-23 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Bellicum Pharmaceuticals (NASDAQ: BLCM) through any online brokerage.
Other companies in Bellicum Pharmaceuticals’s space includes: Addex Therapeutics (NASDAQ:ADXN), Midatech Pharma (NASDAQ:MTP), Brickell Biotech (NASDAQ:BBI), Cyclacel Pharmaceuticals (NASDAQ:CYCC) and BioRestorative Therapies (NASDAQ:BRTX).
The latest price target for Bellicum Pharmaceuticals (NASDAQ: BLCM) was reported by Ladenburg Thalmann on Wednesday, February 16, 2022. The analyst firm set a price target for 5.00 expecting BLCM to rise to within 12 months (a possible 273.13% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Bellicum Pharmaceuticals (NASDAQ: BLCM) is $1.34 last updated August 9, 2022, 8:00 PM UTC.
There are no upcoming dividends for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals’s Q3 earnings are confirmed for Thursday, November 3, 2022.
There is no upcoming split for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.